U.S., May 16 -- ClinicalTrials.gov registry received information related to the study (NCT06972511) titled 'Maximal Tumor Eradication for Oligometastatic Prostate Cancer' on April 26, 2023.
Brief Summary: In China, the incidence of prostate cancer is increasing in recent years, and it has ranked 5th among common male tumors and 1st in urinary tumors. Unlike developed countries in Europe and the United States, in China, because prostate-specific antigen (PSA) screening has not been widely popularized, and early prostate cancer is mostly asymptomatic, about 13%-26% of prostate cancer patients have progressed to metastatic hormone-sensitive prostate cancer (mHSPC) at the time of initial diagnosis. Compared with localized prostate cancer, the ...